A

Assembly Biosciences
D

ASMB

13.650
USD
0.03
(0.22%)
مغلق
حجم التداول
103
الربح لكل سهم
-5
العائد الربحي
-
P/E
-2
حجم السوق
104,252,598
أصول ذات صلة
ALNY
ALNY
0.47
(0.16%)
289.82 USD
A
ARWR
-0.250
(-1.62%)
15.140 USD
C
CRSP
-0.760
(-2.02%)
36.850 USD
E
EDIT
-0.07000
(-4.32%)
1.55000 USD
E
ESPR
-0.01830
(-2.27%)
0.78900 USD
I
IONS
-0.295
(-0.89%)
32.970 USD
N
NTLA
-0.30500
(-3.22%)
9.17000 USD
R
RGNX
-0.13000
(-1.32%)
9.73000 USD
V
VYGR
-0.05500
(-1.85%)
2.91500 USD
المزيد
الأخبار المقالات

العنوان: Assembly Biosciences

القطاع: Healthcare
الصناعة: Biotechnology
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.